Article Text

Download PDFPDF

4CPS-102 Measurement of health outcomes of pomalidomide, cyclophosphamide and dexamethasone combination in adult patients with relapsed and refractory multiple myeloma
  1. C Alarcon-Payer1,
  2. S Cano Domínguez1,
  3. A Jiménez Morales1,
  4. R Ríos Tamayo2,
  5. M Jurado Chacón2
  1. 1Hospital Universitario Virgen de las Nieves, Servicio de Farmacia, Granada, Spain
  2. 2Hospital Universitario Virgen de las Nieves, Servicio de Haematología, Granada, Spain


Background Multiple myeloma is a plasma cell malignancy that accounts for 1% of all cancers. Despite available therapies, the disease remains uniformly fatal, and patients who have received prior lenalidomide and bortezomib have a median overall survival of 9 months. Pomalidomide and low-dose dexamethasone (PomDex) is standard treatment for lenalidomide refractory myeloma patients who have received >2 prior therapies. Combination therapy is often used in clinical practice in an attempt to overcome drug/clone resistance.

Purpose To measure health outcomes in the combination of pomalidomide, cyclophosphamide and dexamethasone (PomCyDex) in adult patients with relapsed and refractory multiple myeloma (RRMM).

Material and methods Three-year prospective observational study of 31 cases of RRMM. To measure the health outcomes obtained with the PomCyDex combination in a third-level hospital we used median progression-free survival as the main variable to assess if the combination is effective. Age, number of previous treatment lines and most frequent adverse reactions were also measured.

Results Thirty-one RRMM cases were analysed, (48.3%: women; 51.6%: men). The mean age was 68 years. The health outcomes measured in our clinical practice were as follows: 38.7% of the patients were treated with PomCyDex in the third line, 12.9% in the fourth line, 25.8% in the fifth line, 19.3% in the sixth line and 3.2% in the seventh line. The mean number of PomCyDex cycles received was nine. The median PFS was 9.9 months. The PomCydex combination was shown to improve PFS by an additional 5.9 months compared to PomDex-only patients receiving a 4 month PFS (MM-003). The most frequent adverse reactions observed were neutropaenia (38%), anaemia (11%) and thrombocytopaenia (5%).

Conclusion Health outcomes of the PomCyDex combination are similar to those published by Baz et al 1 and is considered an effective combination. The PomCyDex combination is well tolerated in most patients and is therefore considered a safe treatment.

Reference and/or acknowledgements

  1. Baz RC, et al. Blood 2016;127:2561–8.

Reference and/or acknowledgementsNo conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.